Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Hope Rugo (ucsf)
Headshot of Hope Rugo
Hope Rugo

Description

Summary

Official Title

A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

Details

Keywords

Breast Cancer, Breast Neoplasms, Paclitaxel, Maytansine, Ado-Trastuzumab Emtansine, Trastuzumab, Trastuzumab emtansine, Trastuzumab emtansine (T-DM1), Paclitaxel + Trastuzumab

Eligibility

Locations

  • University of California San Francisco
    San Francisco California 94115 United States
  • Mountain States Tumor Institute
    Nampa Idaho 83686 United States

Lead Scientist at University of California Health

  • Hope Rugo (ucsf)
    Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Dana-Farber Cancer Institute
ID
NCT01853748
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 512 people participating
Last Updated